Insight in eukaryotic ABC transporter function by mutation analysis
暂无分享,去创建一个
[1] S. Cole,et al. Mutations of charged amino acids in or near the transmembrane helices of the second membrane spanning domain differentially affect the substrate specificity and transport activity of the multidrug resistance protein MRP1 (ABCC1). , 2004, Molecular pharmacology.
[2] A. Kitzis,et al. The cystic fibrosis mutation G1349D within the signature motif LSHGH of NBD2 abolishes the activation of CFTR chloride channels by genistein. , 2004, Biochemical pharmacology.
[3] B. Papsin,et al. Misfolding diverts CFTR from recycling to degradation , 2004, The Journal of cell biology.
[4] K. Ueda,et al. How does P-glycoprotein recognize its substrates? , 1997, Seminars in cancer biology.
[5] S. Cole,et al. Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. , 2005, Pharmacogenetics and genomics.
[6] J. Falcón-Pérez,et al. Functional Domain Analysis of the Yeast ABC Transporter Ycf1p by Site-directed Mutagenesis* , 1999, The Journal of Biological Chemistry.
[7] J. Falcón-Pérez,et al. Domain Interactions in the Yeast ATP Binding Cassette Transporter Ycf1p: Intragenic Suppressor Analysis of Mutations in the Nucleotide Binding Domains , 2001, Journal of bacteriology.
[8] F. Ashcroft,et al. The essential role of the Walker A motifs of SUR1 in K‐ATP channel activation by Mg‐ADP and diazoxide , 1997, The EMBO journal.
[9] X. Chang,et al. Mutation of potential phosphorylation sites in the recombinant R domain of the cystic fibrosis transmembrane conductance regulator has significant effects on domain conformation. , 1995, Biochemical and biophysical research communications.
[10] S. Seino,et al. Cooperative binding of ATP and MgADP in the sulfonylurea receptor is modulated by glibenclamide. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[11] G. Ames,et al. Structure-function analysis of the histidine permease and comparison with cystic fibrosis mutations. , 1991, The Journal of biological chemistry.
[12] N. McCarty. Permeation through the CFTR chloride channel. , 2000, The Journal of experimental biology.
[13] M. Welsh,et al. Mutations in CFTR associated with mild-disease-form CI- channels with altered pore properties , 1993, Nature.
[14] S. Yamashita,et al. C-Terminal Tails of Sulfonylurea Receptors Control ADP-Induced Activation and Diazoxide Modulation of ATP-Sensitive K+ Channels , 2000, Circulation research.
[15] Z. Bebők,et al. Ablation of Internalization Signals in the Carboxyl-terminal Tail of the Cystic Fibrosis Transmembrane Conductance Regulator Enhances Cell Surface Expression* , 2002, The Journal of Biological Chemistry.
[16] K. Liliom,et al. The Role of the Conserved Glycines of ATP-binding Cassette Signature Motifs of MRP1 in the Communication between the Substrate-binding Site and the Catalytic Centers* , 2004, Journal of Biological Chemistry.
[17] M. Azzaria,et al. Discrete mutations introduced in the predicted nucleotide-binding sites of the mdr1 gene abolish its ability to confer multidrug resistance , 1989, Molecular and cellular biology.
[18] T. Furukawa,et al. Function of the ABC signature sequences in the human multidrug resistance protein 1. , 2004, Molecular pharmacology.
[19] H. Omote,et al. Improved energy coupling of human P-glycoprotein by the glycine 185 to valine mutation. , 2004, Biochemistry.
[20] A. E. Senior,et al. Synergy between Conserved ABC Signature Ser Residues in P-glycoprotein Catalysis* , 2004, Journal of Biological Chemistry.
[21] U. Quast,et al. The mutation Y1206S increases the affinity of the sulphonylurea receptor SUR2A for glibenclamide and enhances the effects of coexpression with Kir6.2 , 2005, British journal of pharmacology.
[22] D. Clarke,et al. Functional consequences of proline mutations in the predicted transmembrane domain of P-glycoprotein. , 1993, The Journal of biological chemistry.
[23] A. E. Senior,et al. Properties of P-glycoprotein with Mutations in the “Catalytic Carboxylate” Glutamate Residues* , 2004, Journal of Biological Chemistry.
[24] R. Callaghan,et al. The coupling mechanism of P‐glycoprotein involves residue L339 in the sixth membrane spanning segment , 2005, FEBS letters.
[25] H. Osswald,et al. Effect of two amino acids in TM17 of Sulfonylurea receptor SUR1 on the binding of ATP-sensitive K+ channel modulators. , 2004, Diabetes.
[26] R. Kopito,et al. Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis. , 2002, The Journal of clinical investigation.
[27] D. Clarke,et al. Processing Mutations Located throughout the Human Multidrug Resistance P-glycoprotein Disrupt Interactions between the Nucleotide Binding Domains* , 2004, Journal of Biological Chemistry.
[28] B. Nilius,et al. Characterization of 19 disease-associated missense mutations in the regulatory domain of the cystic fibrosis transmembrane conductance regulator. , 1998, Human molecular genetics.
[29] Fei Wang,et al. Deletion of phenylalanine 508 causes attenuated phosphorylation‐dependent activation of CFTR chloride channels , 2000, The Journal of physiology.
[30] A. Babenko,et al. The C Terminus of SUR1 Is Required for Trafficking of KATP Channels* , 1999, The Journal of Biological Chemistry.
[31] Douglas C. Rees,et al. The E. coli BtuCD Structure: A Framework for ABC Transporter Architecture and Mechanism , 2002, Science.
[32] E. Mikhailova,et al. Molecular structure of the glibenclamide binding site of the β‐cell KATP channel , 2001 .
[33] Marc-Etienne Rousseau,et al. Mutational analysis of conserved carboxylate residues in the nucleotide binding sites of P-glycoprotein. , 2000, Biochemistry.
[34] M. Ishii,et al. Mutation in Nucleotide-Binding Domains of Sulfonylurea Receptor 2 Evokes Na-ATP-Dependent Activation of ATP-Sensitive K+ Channels: Implication for Dimerization of Nucleotide-Binding Domains to Induce Channel Opening , 2004, Molecular Pharmacology.
[35] Kai Du,et al. The ΔF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR , 2005, Nature Structural &Molecular Biology.
[36] Y. Horio,et al. A Novel Sulfonylurea Receptor Forms with BIR (Kir6.2) a Smooth Muscle Type ATP-sensitive K+ Channel* , 1996, The Journal of Biological Chemistry.
[37] U. Quast,et al. Characterization of a mutant sulfonylurea receptor SUR2B with high affinity for sulfonylureas and openers: differences in the coupling to Kir6.x subtypes. , 2001, Molecular pharmacology.
[38] J. Riordan,et al. The First Nucleotide Binding Domain of Cystic Fibrosis Transmembrane Conductance Regulator Is a Site of Stable Nucleotide Interaction, whereas the Second Is a Site of Rapid Turnover* , 2002, The Journal of Biological Chemistry.
[39] D. Schrenk,et al. A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. , 2002, Pharmacogenetics.
[40] J. Ruysschaert,et al. Mistargeted MRPdeltaF728 mutant is rescued by intracellular GSH. , 2004, FEBS letters.
[41] G. Tusnády,et al. Membrane topology distinguishes a subfamily of the ATP‐binding cassette (ABC) transporters , 1997, FEBS letters.
[42] J. Schlessinger,et al. Cooperativity in associating proteins. Monomer-dimer equilibrium coupled to ligand binding. , 1974, Biochemistry.
[43] C. Vandenberg,et al. Membrane Targeting of ATP-sensitive Potassium Channel , 2002, The Journal of Biological Chemistry.
[44] M. Welsh,et al. Contribution of Proline Residues in the Membrane-spanning Domains of Cystic Fibrosis Transmembrane Conductance Regulator to Chloride Channel Function* , 1996, The Journal of Biological Chemistry.
[45] S. Cole,et al. Role of two adjacent cytoplasmic tyrosine residues in MRP1 (ABCC1) transport activity and sensitivity to sulfonylureas. , 2005, Biochemical pharmacology.
[46] F. Ashcroft,et al. 3‐D structural and functional characterization of the purified KATP channel complex Kir6.2–SUR1 , 2005, The EMBO journal.
[47] F. Collins,et al. Functional roles of the nucleotide-binding folds in the activation of the cystic fibrosis transmembrane conductance regulator. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[48] R. Evers,et al. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. , 2000, Molecular pharmacology.
[49] J. Ruysschaert,et al. Mistargeted MRPΔF728 mutant is rescued by intracellular GSH , 2004 .
[50] J. Marshall,et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis , 1990, Cell.
[51] M. Nishi,et al. A region of the sulfonylurea receptor critical for a modulation of ATP‐sensitive K+ channels by G‐protein βγ‐subunits , 2000 .
[52] T. Hwang,et al. Genistein potentiates wild-type and delta F508-CFTR channel activity. , 1997, The American journal of physiology.
[53] M. Horie,et al. Functionally distinct phospho-forms underlie incremental activation of protein kinase-regulated Cl- conductance in mammalian heart , 1993, The Journal of general physiology.
[54] E. Epping,et al. Mutational Disruption of Plasma Membrane Trafficking of Saccharomyces cerevisiae Yor1p, a Homologue of Mammalian Multidrug Resistance Protein , 1999, Molecular and Cellular Biology.
[55] A. Powe,et al. Mutation of Walker‐A lysine 464 in cystic fibrosis transmembrane conductance regulator reveals functional interaction between its nucleotide‐binding domains , 2002, The Journal of physiology.
[56] S. Cole,et al. Molecular Modeling Correctly Predicts the Functional Importance of Phe594 in Transmembrane Helix 11 of the Multidrug Resistance Protein, MRP1 (ABCC1)* , 2004, Journal of Biological Chemistry.
[57] Y. Kurachi,et al. The nucleotide-binding domains of sulfonylurea receptor 2A and 2B play different functional roles in nicorandil-induced activation of ATP-sensitive K+ channels. , 2004, Molecular pharmacology.
[58] S. Cole,et al. Identification of Proline Residues in the Core Cytoplasmic and Transmembrane Regions of Multidrug Resistance Protein 1 (MRP1/ABCC1) Important for Transport Function, Substrate Specificity, and Nucleotide Interactions* , 2004, Journal of Biological Chemistry.
[59] Joseph F. Cotten,et al. Covalent Modification of the Nucleotide Binding Domains of Cystic Fibrosis Transmembrane Conductance Regulator* , 1998, The Journal of Biological Chemistry.
[60] J. Bryan,et al. A Family of Sulfonylurea Receptors Determines the Pharmacological Properties of ATP-Sensitive K+ Channels , 1996, Neuron.
[61] Marc-Etienne Rousseau,et al. Cysteines 431 and 1074 Are Responsible for Inhibitory Disulfide Cross-linking between the Two Nucleotide-binding Sites in Human P-glycoprotein* , 2001, The Journal of Biological Chemistry.
[62] S. Cole,et al. Identification and Characterization of Functionally Important Elements in the Multidrug Resistance Protein 1 COOH-terminal Region* , 2004, Journal of Biological Chemistry.
[63] S. Cole,et al. Identification of an Amino Acid Residue in Multidrug Resistance Protein 1 Critical for Conferring Resistance to Anthracyclines* , 2001, The Journal of Biological Chemistry.
[64] P. Linsdell. Relationship between anion binding and anion permeability revealed by mutagenesis within the cystic fibrosis transmembrane conductance regulator chloride channel pore , 2001, The Journal of physiology.
[65] P. Pedersen,et al. Cystic fibrosis transmembrane conductance regulator: solution structures of peptides based on the Phe508 region, the most common site of disease-causing DeltaF508 mutation. , 1999, Biochemistry.
[66] H. A. Berger,et al. Regulation of the cystic fibrosis transmembrane conductance regulator Cl- channel by negative charge in the R domain. , 1993, The Journal of biological chemistry.
[67] M. Permutt,et al. Functional analyses of novel mutations in the sulfonylurea receptor 1 associated with persistent hyperinsulinemic hypoglycemia of infancy. , 1998, Diabetes.
[68] E Schneider,et al. ATP-binding-cassette (ABC) transport systems: functional and structural aspects of the ATP-hydrolyzing subunits/domains. , 1998, FEMS microbiology reviews.
[69] S. Cole,et al. Mutational Analysis of Ionizable Residues Proximal to the Cytoplasmic Interface of Membrane Spanning Domain 3 of the Multidrug Resistance Protein, MRP1 (ABCC1) , 2004, Journal of Biological Chemistry.
[70] T. Uchiumi,et al. Trafficking and functional defects by mutations of the ATP‐binding domains in MRP2 in patients with Dubin‐Johnson syndrome , 2002, Hepatology.
[71] M. Welsh,et al. Maturation and function of cystic fibrosis transmembrane conductance regulator variants bearing mutations in putative nucleotide-binding domains 1 and 2 , 1991, Molecular and cellular biology.
[72] S. Shyng,et al. Sulfonylureas Correct Trafficking Defects of ATP-sensitive Potassium Channels Caused by Mutations in the Sulfonylurea Receptor* , 2004, Journal of Biological Chemistry.
[73] A. Edelman,et al. Two Mild Cystic Fibrosis-associated Mutations Result in Severe Cystic Fibrosis When Combined in Cis and Reveal a Residue Important for Cystic Fibrosis Transmembrane Conductance Regulator Processing and Function* , 2001, The Journal of Biological Chemistry.
[74] V. Ling,et al. The mechanism of ATP-dependent multidrug transport by P-glycoprotein. , 1998, Acta physiologica Scandinavica. Supplementum.
[75] G. Cutting,et al. A PDZ-binding motif is essential but not sufficient to localize the C terminus of CFTR to the apical membrane. , 2001, Journal of cell science.
[76] I. Pastan,et al. Both ATP sites of human P-glycoprotein are essential but not symmetric. , 1999, Biochemistry.
[77] C. Higgins,et al. Three-dimensional Structures of the Mammalian Multidrug Resistance P-glycoprotein Demonstrate Major Conformational Changes in the Transmembrane Domains upon Nucleotide Binding* , 2003, The Journal of Biological Chemistry.
[78] J. Riordan,et al. ATP Binding to the First Nucleotide-binding Domain of Multidrug Resistance Protein MRP1 Increases Binding and Hydrolysis of ATP and Trapping of ADP at the Second Domain* , 2002, The Journal of Biological Chemistry.
[79] E. Mikhailova,et al. Investigation of the molecular assembly of β‐cell KATP channels , 2000 .
[80] J. Riordan,et al. Disease-associated mutations in cytoplasmic loops 1 and 2 of cystic fibrosis transmembrane conductance regulator impede processing or opening of the channel. , 1997, Biochemistry.
[81] Y. Horio,et al. Sulphonylurea receptor 2B and Kir6.1 form a sulphonylurea‐sensitive but ATP‐insensitive K+ channel. , 1997, The Journal of physiology.
[82] M. Amaral,et al. Unusually common cystic fibrosis mutation in Portugal encodes a misprocessed protein. , 2003, Biochemical and biophysical research communications.
[83] J. Riordan,et al. ATP Binding to the First Nucleotide Binding Domain of Multidrug Resistance-associated Protein Plays a Regulatory Role at Low Nucleotide Concentration, whereas ATP Hydrolysis at the Second Plays a Dominant Role in ATP-dependent Leukotriene C4 Transport* , 2003, Journal of Biological Chemistry.
[84] M. Akabas,et al. Locating the Anion-selectivity Filter of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Channel , 1997, The Journal of general physiology.
[85] S. S. Smith,et al. CFTR activation: additive effects of stimulatory and inhibitory phosphorylation sites in the R domain. , 1997, The American journal of physiology.
[86] Joseph F. Cotten,et al. Cystic Fibrosis-associated Mutations at Arginine 347 Alter the Pore Architecture of CFTR , 1999, The Journal of Biological Chemistry.
[87] R. Frizzell,et al. ATP alters current fluctuations of cystic fibrosis transmembrane conductance regulator: evidence for a three-state activation mechanism , 1994, The Journal of general physiology.
[88] J. Hartman,et al. Cystic fibrosis transmembrane conductance regulator mutations that disrupt nucleotide binding. , 1994, The Journal of clinical investigation.
[89] D. Clarke,et al. The Dileucine Motif at the COOH Terminus of Human Multidrug Resistance P-glycoprotein Is Important for Folding but Not Activity* , 2005, Journal of Biological Chemistry.
[90] J. Riordan,et al. Assembly of functional CFTR chloride channels. , 2005, Annual review of physiology.
[91] S. Cole,et al. Characterization of the role of polar amino acid residues within predicted transmembrane helix 17 in determining the substrate specificity of multidrug resistance protein 3. , 2003, Biochemistry.
[92] R. Evers,et al. The human multidrug resistance-associated protein functionally complements the yeast cadmium resistance factor 1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[93] A. Babenko,et al. Pharmaco-topology of Sulfonylurea Receptors , 2000, The Journal of Biological Chemistry.
[94] C. Deber,et al. Polar residues in membrane domains of proteins: molecular basis for helix-helix association in a mutant CFTR transmembrane segment. , 2002, Biochemistry.
[95] R. Moss,et al. Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. , 1999, American journal of physiology. Cell physiology.
[96] S. Cole,et al. Determinants of the Substrate Specificity of Multidrug Resistance Protein 1 , 2002, The Journal of Biological Chemistry.
[97] P. Melera,et al. Mutations in the sixth transmembrane domain of P-glycoprotein that alter the pattern of cross-resistance also alter sensitivity to cyclosporin A reversal. , 1997, Molecular pharmacology.
[98] M. Gottesman,et al. Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.
[99] R. Béliveau,et al. Identification of the cyclosporin-binding site in P-glycoprotein. , 1998, Biochemistry.
[100] M. Welsh,et al. Mechanism of dysfunction of two nucleotide binding domain mutations in cystic fibrosis transmembrane conductance regulator that are associated with pancreatic sufficiency. , 1995, The EMBO journal.
[101] S. Seino,et al. MgADP Antagonism to Mg2+-independent ATP Binding of the Sulfonylurea Receptor SUR1* , 1997, The Journal of Biological Chemistry.
[102] A. Nairn,et al. Control of CFTR channel gating by phosphorylation and nucleotide hydrolysis. , 1999, Physiological reviews.
[103] I. Pastan,et al. Contribution to substrate specificity and transport of nonconserved residues in transmembrane domain 12 of human P-glycoprotein. , 1998, Biochemistry.
[104] D. Thiele,et al. A yeast metal resistance protein similar to human cystic fibrosis transmembrane conductance regulator (CFTR) and multidrug resistance-associated protein. , 1994, The Journal of biological chemistry.
[105] S. Cole,et al. Functional Importance of Polar and Charged Amino Acid Residues in Transmembrane Helix 14 of Multidrug Resistance Protein 1 (MRP1/ABCC1) , 2003, Journal of Biological Chemistry.
[106] J. Riordan,et al. Endocytic trafficking routes of wild type and DeltaF508 cystic fibrosis transmembrane conductance regulator. , 2004, Molecular biology of the cell.
[107] Y. Wang,et al. Walker mutations reveal loose relationship between catalytic and channel-gating activities of purified CFTR (cystic fibrosis transmembrane conductance regulator). , 1999, Biochemistry.
[108] Jianjie Ma,et al. Function of the second nucleotide‐binding fold in the CFTR chloride channel , 1999, FEBS letters.
[109] P. Linsdell,et al. Molecular Determinants and Role of An Anion Binding Site in the External Mouth of the CFTR Chloride Channel Pore , 2003, The Journal of physiology.
[110] L. Huan,et al. A Conserved Region of the R Domain of Cystic Fibrosis Transmembrane Conductance Regulator Is Important in Processing and Function* , 1998, Journal of Biological Chemistry.
[111] F. Ashcroft,et al. Identification of a functionally important negatively charged residue within the second catalytic site of the SUR1 nucleotide-binding domains. , 2004, Diabetes.
[112] John F Hunt,et al. Cooperative, ATP-dependent Association of the Nucleotide Binding Cassettes during the Catalytic Cycle of ATP-binding Cassette Transporters* , 2002, The Journal of Biological Chemistry.
[113] Xuehong Liu,et al. CFTR: a cysteine at position 338 in TM6 senses a positive electrostatic potential in the pore. , 2004, Biophysical journal.
[114] J. Bryan,et al. Molecular biology of adenosine triphosphate-sensitive potassium channels. , 1999, Endocrine reviews.
[115] Pavel Strop,et al. The structures of BtuCD and MscS and their implications for transporter and channel function , 2003, FEBS letters.
[116] D. Clarke,et al. Defining the Drug-binding Site in the Human Multidrug Resistance P-glycoprotein Using a Methanethiosulfonate Analog of Verapamil, MTS-verapamil* , 2001, The Journal of Biological Chemistry.
[117] C. Partridge,et al. Identification and Pharmacological Correction of a Membrane Trafficking Defect Associated with a Mutation in the Sulfonylurea Receptor Causing Familial Hyperinsulinism* , 2001, The Journal of Biological Chemistry.
[118] B. Nilius,et al. Phosphorylation site independent single R‐domain mutations affect CFTR channel activity , 1998, FEBS letters.
[119] L. Reuss,et al. Potentiation of effect of PKA stimulation of Xenopus CFTR by activation of PKC: role of NBD2. , 2004, American journal of physiology. Cell physiology.
[120] Jue Chen,et al. ATP-binding cassette transporters in bacteria. , 2004, Annual review of biochemistry.
[121] S. Ryu,et al. Identification of Basic Residues Involved in Drug Export Function of Human Multidrug Resistance-associated Protein 2* , 2000, The Journal of Biological Chemistry.
[122] L. D. Howell,et al. Stimulatory and inhibitory protein kinase C consensus sequences regulate the cystic fibrosis transmembrane conductance regulator , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[123] P. Greengard,et al. Phosphorylation of the cystic fibrosis transmembrane conductance regulator. , 1992, The Journal of biological chemistry.
[124] C. Vandenberg,et al. Membrane Topology of the Amino-terminal Region of the Sulfonylurea Receptor* , 1999, The Journal of Biological Chemistry.
[125] F. Ashcroft,et al. Potassium channel regulation , 2003, EMBO Reports.
[126] X. Chang,et al. Phosphorylation of protein kinase C sites in NBD1 and the R domain control CFTR channel activation by PKA , 2003, The Journal of physiology.
[127] S. Seino,et al. Physiological and pathophysiological roles of ATP-sensitive K+ channels. , 2003, Progress in biophysics and molecular biology.
[128] Ycf1‐dependent cadmium detoxification by yeast requires phosphorylation of residues Ser908 and Thr911 , 2004, FEBS letters.
[129] P. Gros,et al. Nucleotide-induced conformational changes in P-glycoprotein and in nucleotide binding site mutants monitored by trypsin sensitivity. , 2000, Biochemistry.
[130] Paola Vergani,et al. NBD1 might remain nucleotide-bound throughout CFTR channel gating , 2002 .
[131] J. Bryan,et al. Potassium channel openers require ATP to bind to and act through sulfonylurea receptors , 1998, The EMBO journal.
[132] D. Clarke,et al. Rapid Purification of Human P-glycoprotein Mutants Expressed Transiently in HEK 293 Cells by Nickel-Chelate Chromatography and Characterization of their Drug-stimulated ATPase Activities (*) , 1995, The Journal of Biological Chemistry.
[133] G. Lukács,et al. Multiple endocytic signals in the C-terminal tail of the cystic fibrosis transmembrane conductance regulator. , 2001, The Biochemical journal.
[134] P. Linsdell,et al. Point mutations in the pore region directly or indirectly affect glibenclamide block of the CFTR chloride channel , 2002, Pflügers Archiv.
[135] M. Welsh,et al. Structure and function of the CFTR chloride channel. , 1999, Physiological reviews.
[136] F. Collins,et al. Molecular basis of defective anion transport in L cells expressing recombinant forms of CFTR. , 1993, Human molecular genetics.
[137] M. Welsh,et al. Stimulation of CFTR activity by its phosphorylated R domain , 1997, Nature.
[138] J. Schellens,et al. Evidence for Two Interacting Ligand Binding Sites in Human Multidrug Resistance Protein 2 (ATP Binding Cassette C2)* , 2003, Journal of Biological Chemistry.
[139] F. Gally,et al. The Size of a Single Residue of the Sulfonylurea Receptor Dictates the Effectiveness of KATP Channel Openers , 2005, Molecular Pharmacology.
[140] Arg352 is a major determinant of charge selectivity in the cystic fibrosis transmembrane conductance regulator chloride channel. , 1999, Biochemistry.
[141] P. Gros,et al. Mutations in either nucleotide-binding site of P-glycoprotein (Mdr3) prevent vanadate trapping of nucleotide at both sites. , 1998, Biochemistry.
[142] 松岡 哲郎. C-Terminal Tails of Sulfonylurea Receptors Control ADP-Induced Activation and Diazoxide Modulation of ATP-Sensitive K+ Channels , 2003 .
[143] M. Welsh,et al. Effect of deletion mutations on the function of CFTR chloride channels. , 1993, Receptors & channels.
[144] A. Terzic,et al. Signaling in Channel/Enzyme Multimers ATPase Transitions in SUR Module Gate ATP-Sensitive K+ Conductance , 2001, Neuron.
[145] C. Stanley,et al. Familial leucine-sensitive hypoglycemia of infancy due to a dominant mutation of the beta-cell sulfonylurea receptor. , 2004, The Journal of clinical endocrinology and metabolism.
[146] T. Amachi,et al. Different Binding Properties and Affinities for ATP and ADP among Sulfonylurea Receptor Subtypes, SUR1, SUR2A, and SUR2B* , 2000, The Journal of Biological Chemistry.
[147] John A. Tainer,et al. Structural Biology of Rad50 ATPase ATP-Driven Conformational Control in DNA Double-Strand Break Repair and the ABC-ATPase Superfamily , 2000, Cell.
[148] M. Welsh,et al. An Intrinsic Adenylate Kinase Activity Regulates Gating of the ABC Transporter CFTR , 2003, Cell.
[149] K. Locher,et al. ABC transporter architecture and mechanism: implications from the crystal structures of BtuCD and BtuF , 2004, FEBS letters.
[150] F. Ashcroft. Adenosine 5'-triphosphate-sensitive potassium channels. , 1988, Annual review of neuroscience.
[151] K. Kirk,et al. A cluster of negative charges at the amino terminal tail of CFTR regulates ATP‐dependent channel gating , 2001, The Journal of physiology.
[152] S. Cole,et al. Role of the NH2-terminal membrane spanning domain of multidrug resistance protein 1/ABCC1 in protein processing and trafficking. , 2005, Molecular biology of the cell.
[153] X. Chang,et al. Mutation of the Aromatic Amino Acid Interacting with Adenine Moiety of ATP to a Polar Residue Alters the Properties of Multidrug Resistance Protein 1* , 2004, Journal of Biological Chemistry.
[154] Z. Sauna,et al. Importance of the conserved Walker B glutamate residues, 556 and 1201, for the completion of the catalytic cycle of ATP hydrolysis by human P-glycoprotein (ABCB1). , 2002, Biochemistry.
[155] K. Kirk,et al. Cysteine Substitutions Reveal Dual Functions of the Amino-terminal Tail in Cystic Fibrosis Transmembrane Conductance Regulator Channel Gating* , 2001, The Journal of Biological Chemistry.
[156] L. Tsui,et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. , 1989, Science.
[157] Karl Kuchler,et al. ABC proteins : from bacteria to man , 2003 .
[158] S. Cole,et al. Mutation of proline residues in the NH(2)-terminal region of the multidrug resistance protein, MRP1 (ABCC1): effects on protein expression, membrane localization, and transport function. , 2003, Biochimica et biophysica acta.
[159] P. Melera,et al. Transmembrane domain (TM) 9 represents a novel site in P-glycoprotein that affects drug resistance and cooperates with TM6 to mediate [125I]iodoarylazidoprazosin labeling. , 2001, Molecular pharmacology.
[160] D. Clarke,et al. Correction of Defective Protein Kinesis of Human P-glycoprotein Mutants by Substrates and Modulators* , 1997, The Journal of Biological Chemistry.
[161] M. Welsh,et al. Regulation of the Cystic Fibrosis Transmembrane Conductance Regulator Cl− Channel by Its R Domain* , 2001, The Journal of Biological Chemistry.
[162] D. Clarke,et al. ATP hydrolysis promotes interactions between the extracellular ends of transmembrane segments 1 and 11 of human multidrug resistance P-glycoprotein. , 2005, Biochemistry.
[163] N. McCarty,et al. Interaction between permeation and gating in a putative pore domain mutant in the cystic fibrosis transmembrane conductance regulator. , 2000, Biophysical journal.
[164] A. Terzic,et al. ATPase activity of the sulfonylurea receptor: a catalytic function for the KATP channel complex , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[165] H. Okumura,et al. Functional comparison between YCF1 and MRP1 expressed in Sf21 insect cells. , 2000, Biochemical and biophysical research communications.
[166] S. Cole,et al. Photolabeling of Human and Murine Multidrug Resistance Protein 1 with the High Affinity Inhibitor [125I]LY475776 and Azidophenacyl-[35S]Glutathione* , 2002, The Journal of Biological Chemistry.
[167] J. Walker,et al. Distantly related sequences in the alpha‐ and beta‐subunits of ATP synthase, myosin, kinases and other ATP‐requiring enzymes and a common nucleotide binding fold. , 1982, The EMBO journal.
[168] D. Rees,et al. In vitro functional characterization of BtuCD-F, the Escherichia coli ABC transporter for vitamin B12 uptake. , 2005, Biochemistry.
[169] B. Sankaran,et al. Both P-glycoprotein Nucleotide-binding Sites Are Catalytically Active (*) , 1995, The Journal of Biological Chemistry.
[170] J. Gustafson,et al. Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.
[171] M. Welsh,et al. Mutations That Change the Position of the Putative γ-Phosphate Linker in the Nucleotide Binding Domains of CFTR Alter Channel Gating* , 2002, The Journal of Biological Chemistry.
[172] C. Nichols,et al. Regulation of KATP Channel Activity by Diazoxide and MgADP , 1997, The Journal of general physiology.
[173] M. Akabas,et al. Identification of cystic fibrosis transmembrane conductance regulator channel-lining residues in and flanking the M6 membrane-spanning segment. , 1996, Biophysical journal.
[174] D. Clarke,et al. The “LSGGQ” Motif in Each Nucleotide-binding Domain of Human P-glycoprotein Is Adjacent to the Opposing Walker A Sequence* , 2002, The Journal of Biological Chemistry.
[175] R. Evers,et al. Role of the N-terminal Transmembrane Region of the Multidrug Resistance Protein MRP2 in Routing to the Apical Membrane in MDCKII Cells* , 2002, The Journal of Biological Chemistry.
[176] J. Riordan,et al. Crystallographic and single-particle analyses of native- and nucleotide-bound forms of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. , 2005, Biochemical Society transactions.
[177] G. Lukács,et al. Conformational and Temperature-sensitive Stability Defects of the ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator in Post-endoplasmic Reticulum Compartments* , 2001, The Journal of Biological Chemistry.
[178] D. Clarke,et al. Merck Frosst Award Lecture 1998. Molecular dissection of the human multidrug resistance P-glycoprotein. , 1999, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[179] D. Clarke,et al. Functional consequences of glycine mutations in the predicted cytoplasmic loops of P-glycoprotein. , 1994, The Journal of biological chemistry.
[180] H. A. Berger,et al. Fluoride stimulates cystic fibrosis transmembrane conductance regulator Cl- channel activity. , 1998, American journal of physiology. Lung cellular and molecular physiology.
[181] P. Gros,et al. Analysis of catalytic carboxylate mutants E552Q and E1197Q suggests asymmetric ATP hydrolysis by the two nucleotide-binding domains of P-glycoprotein. , 2003, Biochemistry.
[182] A. E. Senior,et al. Conserved Walker A Ser Residues in the Catalytic Sites of P-glycoprotein Are Critical for Catalysis and Involved Primarily at the Transition State Step* , 2000, The Journal of Biological Chemistry.
[183] S. Cole,et al. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. , 2005, Toxicology and applied pharmacology.
[184] L. Huan,et al. Perturbation of the Pore of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Inhibits Its ATPase Activity* , 2001, The Journal of Biological Chemistry.
[185] Michael J. Hartshorn,et al. Structural model of ATP-binding proteing associated with cystic fibrosis, multidrug resistance and bacterial transport , 1990, Nature.
[186] A. E. Senior,et al. Combined Mutation of Catalytic Glutamate Residues in the Two Nucleotide Binding Domains of P-glycoprotein Generates a Conformation That Binds ATP and ADP Tightly* , 2004, Journal of Biological Chemistry.
[187] C. Higgins,et al. Three-dimensional Structure of P-glycoprotein , 2005, Journal of Biological Chemistry.
[188] Fei Wang,et al. Gating of Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channels by Adenosine Triphosphate Hydrolysis , 1999, The Journal of general physiology.
[189] Y. Kurachi,et al. Molecular aspects of ATP-sensitive K+ channels in the cardiovascular system and K+ channel openers. , 2000, Pharmacology & therapeutics.
[190] L. Tsui,et al. Multi-ion pore behaviour in the CFTR chloride channel , 1993, Nature.
[191] D. Keppler,et al. CHAPTER 20 – MRP2, THE APICAL EXPORT PUMP FOR ANIONIC CONJUGATES , 2003 .
[192] A. Verkman,et al. Expression and characterization of the NBD1-R domain region of CFTR: evidence for subunit-subunit interactions. , 1998, Biochemistry.
[193] E. Welker,et al. Characterization of the human multidrug resistance protein containing mutations in the ATP-binding cassette signature region. , 1997, The Biochemical journal.
[194] S. Cole,et al. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. , 2004, Current drug metabolism.
[195] P. Linsdell,et al. Extent of the selectivity filter conferred by the sixth transmembrane region in the CFTR chloride channel pore , 2003, Molecular membrane biology.
[196] R. Kopito,et al. Cysteine residues in the nucleotide binding domains regulate the conductance state of CFTR channels. , 2002, Biophysical journal.
[197] M. Gottesman,et al. Altered Drug-stimulated ATPase Activity in Mutants of the Human Multidrug Resistance Protein (*) , 1996, The Journal of Biological Chemistry.
[198] Joseph F. Cotten,et al. Effect of Cystic Fibrosis-associated Mutations in the Fourth Intracellular Loop of Cystic Fibrosis Transmembrane Conductance Regulator* , 1996, The Journal of Biological Chemistry.
[199] M. Macek,et al. Missense mutation (G480C) in the CFTR gene associated with protein mislocalization but normal chloride channel activity. , 1995, Human molecular genetics.
[200] F. Collins,et al. CFTR: the nucleotide binding folds regulate the accessibility and stability of the activated state , 1996, The Journal of general physiology.
[201] R. Beauwens,et al. Expression and intracellular processing of chimeric and mutant CFTR molecules. , 2000, Biochimica et biophysica acta.
[202] N. McCarty,et al. Voltage-sensitive gating induced by a mutation in the fifth transmembrane domain of CFTR. , 2002, American journal of physiology. Lung cellular and molecular physiology.
[203] K. Ito,et al. Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. , 2001, The Journal of biological chemistry.
[204] S. Higuchi,et al. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. , 2001, Pharmacogenetics.
[205] D. Clarke,et al. Location of the Rhodamine-binding Site in the Human Multidrug Resistance P-glycoprotein* , 2002, The Journal of Biological Chemistry.
[206] D. Clarke,et al. Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound. , 2005, Molecular pharmaceutics.
[207] I. Tsigelny,et al. Identification of molecular determinants that modulate trafficking of ΔF508 CFTR, the mutant ABC transporter associated with cystic fibrosis , 2007, Cell Biochemistry and Biophysics.
[208] C. B. Roth,et al. Structure of MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette (ABC) transporters. , 2001, Science.
[209] J. Riordan,et al. Protein kinase A (PKA) still activates CFTR chloride channel after mutagenesis of all 10 PKA consensus phosphorylation sites. , 1993, The Journal of biological chemistry.
[210] M. Welsh,et al. Normal gating of CFTR requires ATP binding to both nucleotide-binding domains and hydrolysis at the second nucleotide-binding domain. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[211] F. Ashcroft,et al. Identification of the high-affinity tolbutamide site on the SUR1 subunit of the K(ATP) channel. , 1999, Diabetes.
[212] I. Pastan,et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.
[213] B. Sarkadi,et al. Functional studies on the MRP1 multidrug transporter: characterization of ABC-signature mutant variants. , 2004, Anticancer research.
[214] A. Terzic,et al. Tandem Function of Nucleotide Binding Domains Confers Competence to Sulfonylurea Receptor in Gating ATP-sensitive K+ Channels* , 2002, The Journal of Biological Chemistry.
[215] A. Rzhetsky,et al. The human ATP-binding cassette (ABC) transporter superfamily. , 2001, Genome research.
[216] Joseph F. Cotten,et al. Covalent Modification of the Regulatory Domain Irreversibly Stimulates Cystic Fibrosis Transmembrane Conductance Regulator* , 1997, The Journal of Biological Chemistry.
[217] P. Maloney,et al. Intracellular Cysteines of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulate Channel Gating , 2002, Cellular Physiology and Biochemistry.
[218] P. Linsdell,et al. Multi-Ion Mechanism for Ion Permeation and Block in the Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel , 1997, The Journal of general physiology.
[219] L. Cui,et al. Mutations of the Walker B motif in the first nucleotide binding domain of multidrug resistance protein MRP1 prevent conformational maturation. , 2001, Archives of biochemistry and biophysics.
[220] S. S. Smith,et al. Cystic fibrosis transmembrane conductance regulator (CFTR) anion binding as a probe of the pore. , 1998, Biophysical journal.
[221] P. Linsdell,et al. Molecular determinants of anion selectivity in the cystic fibrosis transmembrane conductance regulator chloride channel pore. , 2000, Biophysical journal.
[222] J. Bryan,et al. Toward linking structure with function in ATP-sensitive K+ channels. , 2004, Diabetes.
[223] S. Cole,et al. Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1). , 2003, Biochemistry.
[224] S. Seino. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. , 1999, Annual review of physiology.
[225] M. Welsh,et al. Effect of ATP-sensitive K+ channel regulators on cystic fibrosis transmembrane conductance regulator chloride currents , 1992, The Journal of general physiology.
[226] E. Welker,et al. Drug-stimulated Nucleotide Trapping in the Human Multidrug Transporter MDR1 , 1998, The Journal of Biological Chemistry.
[227] P. Linsdell,et al. Molecular determinants of Au(CN)2− binding and permeability within the cystic fibrosis transmembrane conductance regulator Cl− channel pore , 2002, The Journal of physiology.
[228] P. Smith,et al. Cloning and functional expression of the cDNA encoding a novel ATP‐sensitive potassium channel subunit expressed in pancreatic β‐cells, brain, heart and skeletal muscle , 1995 .
[229] Henry A. Lester,et al. Novel pore-lining residues in CFTR that govern permeation and open-channel block , 1994, Neuron.
[230] N. Davies,et al. Proximal C-terminal domain of sulphonylurea receptor 2A interacts with pore-forming Kir6 subunits in KATP channels. , 2004, The Biochemical journal.
[231] A. Edelman,et al. Cystic Fibrosis Phenotype Associated with Pancreatic Insufficiency Does Not Always Reflect the cAMP-dependent Chloride Conductive Pathway Defect , 1997, The Journal of Biological Chemistry.
[232] A. Terzic,et al. Pharmacological plasticity of cardiac ATP-sensitive potassium channels toward diazoxide revealed by ADP. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[233] A. Verkman,et al. Evidence for phosphorylation of serine 753 in CFTR using a novel metal‐ion affinity resin and matrix‐assisted laser desorption mass spectrometry , 1997, Protein science : a publication of the Protein Society.
[234] T. Amachi,et al. ATP Binding Properties of the Nucleotide-binding Folds of SUR1* , 1999, The Journal of Biological Chemistry.
[235] D. Keppler,et al. A common Dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2). , 2003, American journal of physiology. Gastrointestinal and liver physiology.
[236] F. Ashcroft,et al. Mutations in the linker domain of NBD2 of SUR inhibit transduction but not nucleotide binding , 2002, The EMBO journal.
[237] M. Welsh,et al. Structural and functional similarities between the nucleotide-binding domains of CFTR and GTP-binding proteins. , 1995, Biophysical journal.
[238] K. Linton,et al. The ATP switch model for ABC transporters , 2004, Nature Structural &Molecular Biology.
[239] On the Mechanism of MgATP-dependent Gating of CFTR Cl− Channels , 2003, The Journal of general physiology.
[240] J. Bryan,et al. Sulfonylurea receptors: ABC transporters that regulate ATP-sensitive K(+) channels. , 1999, Biochimica et biophysica acta.
[241] A. Holzenburg,et al. The Structure of the Multidrug Resistance Protein 1 (MRP1/ABCC1) , 2001, The Journal of Biological Chemistry.
[242] K. Du,et al. Destabilization of the Transmembrane Domain Induces Misfolding in a Phenotypic Mutant of Cystic Fibrosis Transmembrane Conductance Regulator* , 2005, Journal of Biological Chemistry.
[243] P. Linsdell,et al. Non‐pore lining amino acid side chains influence anion selectivity of the human CFTR Cl− channel expressed in mammalian cell lines , 1998, The Journal of physiology.
[244] P. Gros,et al. Mutations in the nucleotide-binding sites of P-glycoprotein that affect substrate specificity modulate substrate-induced adenosine triphosphatase activity. , 1998, Biochemistry.
[245] M. Welsh,et al. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. , 1991, Science.
[246] Frances M. Ashcroft,et al. Correlating structure and function in ATP-sensitive K+ channels , 1998, Trends in Neurosciences.
[247] S. Shyng,et al. Identification of a Familial Hyperinsulinism-causing Mutation in the Sulfonylurea Receptor 1 That Prevents Normal Trafficking and Function of KATP Channels* , 2002, The Journal of Biological Chemistry.
[248] Preferential Phosphorylation of R-domain Serine 768 Dampens Activation of CFTR Channels by PKA , 2005, The Journal of general physiology.
[249] J. Riordan,et al. Allosteric Interactions between the Two Non-equivalent Nucleotide Binding Domains of Multidrug Resistance Protein MRP1* , 2000, The Journal of Biological Chemistry.
[250] T. Furukawa,et al. A positively charged amino acid proximal to the C-terminus of TM17 of MRP1 is indispensable for GSH-dependent binding of substrates and for transport of LTC4. , 2002, Biochemistry.
[251] H. Lage,et al. Homozygous mutation Arg768Trp in the ABC-transporter encoding gene MRP2/cMOAT/ABCC2 causes Dubin-Johnson syndrome in a Caucasian patient , 2003, Journal of Human Genetics.
[252] C. Vandenberg,et al. Defective trafficking and function of KATP channels caused by a sulfonylurea receptor 1 mutation associated with persistent hyperinsulinemic hypoglycemia of infancy , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[253] I. Pastan,et al. A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol. , 1999, Biochemistry.
[254] P. Linsdell,et al. Asymmetric structure of the cystic fibrosis transmembrane conductance regulator chloride channel pore suggested by mutagenesis of the twelfth transmembrane region. , 2001, Biochemistry.
[255] B. Nilius,et al. Characterization of mutations located in exon 18 of the CFTR gene , 1998, FEBS letters.
[256] Junxia Xie,et al. A Short Segment of the R Domain of Cystic Fibrosis Transmembrane Conductance Regulator Contains Channel Stimulatory and Inhibitory Activities That Are Separable by Sequence Modification* , 2002, The Journal of Biological Chemistry.
[257] J. Riordan,et al. CHAPTER 29 – THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (ABCC7) , 2003 .
[258] L. Tsui,et al. Permeability of Wild-Type and Mutant Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channels to Polyatomic Anions , 1997, The Journal of general physiology.
[259] J. Widdicombe,et al. Structural cues involved in endoplasmic reticulum degradation of G85E and G91R mutant cystic fibrosis transmembrane conductance regulator. , 1997, The Journal of clinical investigation.
[260] A. Duncan,et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.
[261] S. Hecht,et al. Transport of the β-O-Glucuronide Conjugate of the Tobacco-specific Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the Multidrug Resistance Protein 1 (MRP1) , 2001, The Journal of Biological Chemistry.
[262] Junxia Xie,et al. Intermolecular interaction between R domains of cystic fibrosis transmembrane conductance regulator. , 2004, American journal of respiratory cell and molecular biology.
[263] P. Linsdell,et al. Mutation-induced Blocker Permeability and Multiion Block of the CFTR Chloride Channel Pore , 2003, The Journal of general physiology.
[264] K. Gunderson,et al. Conformational states of CFTR associated with channel gating: The role of ATP binding and hydrolysis , 1995, Cell.
[265] S. Michaelis,et al. A Region within a Lumenal Loop of Saccharomyces cerevisiae Ycf1p Directs Proteolytic Processing and Substrate Specificity , 2003, Eukaryotic Cell.
[266] U. Quast,et al. Glibenclamide binding to sulphonylurea receptor subtypes: dependence on adenine nucleotides , 2002, British journal of pharmacology.
[267] R. Kölling,et al. Functional asymmetry of the two nucleotide binding domains in the ABC transporter Ste6 , 2001, Molecular Genetics and Genomics.
[268] S. Cole,et al. Multidrug Resistance Protein , 1998, The Journal of Biological Chemistry.
[269] J. Riordan,et al. Cystic fibrosis-type mutational analysis in the ATP-binding cassette transporter signature of human P-glycoprotein MDR1. , 1994, The Journal of biological chemistry.
[270] I. Holland,et al. ABC-ATPases, adaptable energy generators fuelling transmembrane movement of a variety of molecules in organisms from bacteria to humans. , 1999, Journal of molecular biology.